Posted by Michael Wonder on 25 Aug 2016
CADTH recommends the reimbursement of secukinumab (Cosentyx) for psoriatic arthritis
23 August 2016 - CADTH has issued a final recommendation on the reimbursement of secukinumab (Cosentyx) for patients with psoriatic arthritis.
The CADTH Canadian Drug Expert Committee recommends that secukinumab be reimbursed for the treatment of adult patients with active psoriatic arthritis (PsA), used alone or in combination with methotrexate, when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate if the annual drug plan cost for the treatment of PsA with secukinumab should not exceed the annual drug plan cost of treating PsA with the least costly biologic reimbursed.
